Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European decision on embryo stem cells may undermine medical research

This article was originally published in Clinica

Executive Summary

In an opinion published on 18 October, the European Court of Justice has ruled that a process which involves removal of a stem cell from a human embryo at the blastocyst stage, entailing the destruction of that embryo, is not patentable. The ruling concerns a method invented by Oliver Bruestle of the University of Bonn for converting human embryonic stem cells into nerve cells, and upholds an earlier legal opinion of Advocate General Yves Bott.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT098023

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel